Leucine-rich-repeat kinase 2 (LRRK2), a potential therapeutic target for the treatment of Parkinson’s disease (PD), is highly expressed in monocytes and macrophages and may play a role in the regulation of inflammatory pathways. To determine how LRRK2 protein levels and/or its activity modulate inflammatory cytokine/chemokine levels in human immune cells, isogenic human induced pluripotent stem cells (iPSC) with the LRRK2-activating G2019S mutation, wild-type LRRK2, and iPSC deficient in LRRK2 were differentiated to monocytes and macrophages and stimulated with inflammatory toll-like receptor (TLR) agonists in the presence and absence of LRRK2 kinase inhibitors. The effect of LRRK2 inhibitors and the effect of increasing LRRK2 levels with interferon gamma on TLR-stimulated cytokines were also assessed in primary peripheral blood-derived monocytes. Monocytes and macrophages with the LRRK2 G2019S mutation had significantly higher levels of cytokines and chemokines in culture media following stimulation with TLR agonists compared to isogenic controls. Knockout of LRRK2 impaired phagocytosis but did not significantly affect TLR-mediated cytokine levels. Interferon gamma significantly increased the levels of LRRK2 and phosphorylation of its downstream Rab10 substrate, and potentiated TLR-mediated cytokine levels. LRRK2 kinase inhibitors did not have a major effect on TLR-stimulated cytokine levels. Results suggest that the LRRK2 G2019S mutation may potentiate inflammation following activation of TLRs. However, this was not dependent on LRRK2 kinase activity. Indeed, LRRK2 kinase inhibitors had little effect on TLR-mediated inflammation under the conditions employed in this study.

**INTRODUCTION**

Genetic variation in leucine-rich-repeat kinase 2 (LRRK2) is strongly implicated in the risk of developing the neurodegenerative movement disorder Parkinson’s disease (PD). At least six missense mutations in LRRK2 increase the enzyme’s kinase activity and comprise a frequent cause of autosomal dominantly inherited PD. Common variation in LRRK2 is also associated with a greater risk of idiopathic PD, and increased LRRK2 activity has been measured in brain tissue from PD patients without LRRK2 mutations. Increased LRRK2 activity is pathogenically linked to PD, much effort has gone into the development of small-molecule LRRK2 inhibitors as potential therapeutics. Preclinical studies have suggested the potential efficacy of LRRK2 inhibitors across different models, and indeed, the first LRRK2 inhibitors are currently in early phase clinical trials. However, the biological function of LRRK2 remains unclear and exactly how LRRK2 contributes to the pathogenesis of PD is unknown.

One intriguing aspect of LRRK2 biology is its much higher expression in peripheral immune cells compared to central nervous system cells. Indeed, accumulating evidence indicates a role for LRRK2 in immune cell function and is phosphorylated by IkB kinase family members following activation of toll-like receptors (TLRs). LRRK2 kinase activity has also been implicated in the activation of inflammasome complexes and the host response to ligands of the dendritic receptor. Moreover, LRRK2 variation has also been genetically linked to the susceptibility of infection from M. leprae, and a number of studies have now functionally linked LRRK2 to the clearance of pathogens such as M. tuberculosis and S. typhimurium. Finally, LRRK2 variation has also robustly been linked to the risk of developing inflammatory bowel disease. Collective studies therefore clearly implicate LRRK2 in innate immune responses.

A major aspect of the innate immune pathway is to modulate the host response to pathogens via the production of inflammatory cytokines. Studies predominantly using mice or murine derived immune cells have suggested a role for LRRK2 in the regulation of inflammatory cytokine production. The importance of increasing evidence continues to implicate inflammation in the early pathogenesis of PD. Indeed, the assessment of inflammatory cytokine profiles in LRRK2 G2019S mutation carriers found elevated serum levels of IL1β, TNFα, IL6 and IL12 in a subset of asymptomatic mutation carriers compared to controls, and LRRK2 patients with more severe symptoms present with higher levels of the proinflammatory proteins IL8, MCP1 and MIP1β. Moreover, frequent use of non-steroidal anti-inflammatory medication is associated with reduced penetrance of PD in LRRK2 mutation carriers. Despite the evidence supporting a role for LRRK2 function in the immune system, exactly how LRRK2 modulates inflammatory signalling in human cells is still unclear. We have therefore employed isogenic induced pluripotent stem cell lines (iPSC) with the pathogenic G2019S mutation, LRRK2 knockout, and LRRK2 wild type and differentiated them to monocytes and macrophages. We find evidence that the LRRK2 G2019S mutation can potentiate TLR-mediated cytokines, but we find little effect of LRRK2 inhibitors or LRRK2 knockout on the TLR-stimulated cytokine response.
RESULTS

Differentialization of LRRK2 iPSCs to monocytes and macrophages

To confirm successful differentialization of wild type (WT), G2019S and LRRK2 knockout (KO) isogenic iPSCs to monocytes, suspended cells in the culture media were routinely collected and analysed by flow cytometry (Fig. 1a). The percentage of CD14-positive cells in the collected media varied between rounds of differentialisation, however, the percentage was always similar for the different LRRK2 genotypes within each round (Fig. 1b). The percentage of CD14-positive cells in the collected media was on average 27% across the different collection timepoints, therefore immunomagnetic isolation was used to purify monocyte populations to >90% CD14-positive cells prior to experiments. Flow cytometry was used to assess the expression of additional myeloid markers with CD68 (Fig. 1c) and HLA-DR (Fig. 1d) unchanged between genotypes. In contrast, there was a small but significant reduction in the expression of CCR2 (Fig. 1e) and CD163 (Fig. 1f) in the LRRK2 KO monocytes, compared to the LRRK2 G2019S monocytes. The expression of CD16 was also measured to determine the percentage of classical (CD14+CD16−), intermediate (CD14+CD16+) and non-classical (CD14lowCD16+) monocytes. This uncovered a heterogenous mix of monocyte populations that were not significantly different between the genotypes (Fig. 1g). For functional characterisation, the isolated monocytes were also differentiated to adherent macrophages and phagocytosis was assessed using fluorescent latex beads at 3 (Fig. 1h) and 16 h (Fig. 1i) timepoints. After 3 h, there was a significant reduction in the phagocytosis of the beads by the macrophages with the LRRK2 G2019S mutation compared to WT (Fig. 1h), but no difference was observed between these two genotypes at 16 h (Fig. 1i). In contrast, the LRRK2 KO macrophages showed no difference at the 3 h timepoint, but a significant reduction in the phagocytosis of the latex beads at 16 h compared to both the WT and LRRK2 G2019S macrophages (Fig. 1i). After 16 h, LRRK2 KO macrophages also had a significant reduction in the number of puncta per cell that were formed by the accumulation of fluorescent latex beads, in conjunction with a marked increase in the average area of the puncta per cell (Supplementary Fig. S1). Finally, immunoblotting was used to confirm that LRRK2 KO cells were deficient in LRRK2 protein (Fig. 1j–k). LRRK2 KO cells also had lower levels of Rab10 phosphorylation compared to LRRK2 G2019S cells, whilst Rab10 phosphorylation was not significantly different between LRRK2 G2019S and WT monocytes (Fig. 1i). Weak detection of the LRRK2 S1292 phosphorylation site could be observed only in LRRK2 G2019S cells indicative of increased LRRK2 kinase activity (Fig. 1m). These results show that monocytes/macrophages with different LRRK2 genotypes can be successfully differentiated from the iPSCs.

Increased TLR-stimulated cytokines with the LRRK2 G2019S mutation

Monocytes from the different cell lines were then stimulated with TLR agonists to determine the effect of LRRK2 genotype on the levels of cytokines released into the tissue culture media. Multivariate analysis of the measured cytokine levels in the tissue culture media 24 h after stimulation indicated a significant effect of LRRK2 genotype to influence cytokines for cells stimulated with LPS (P = 0.002, Fig. 2a), Pam3CSK4 (P = 0.001, Fig. 2b) and CLO97 (P = 0.019, Fig. 2c). Evaluation of the estimated marginal means clearly indicated the significant effect of genotype was driven by increase cytokine levels in the tissue culture media of cells with LRRK2 G2109S mutation. Indeed, the vast majority of cytokines were increased in the tissue culture media of LRRK2 G2109S cells for all three of the MyD88-dependent TLR agonists used (Fig. 2a–c). In contrast to LRRK2 G2019S, LRRK2 KO monocytes produced similar levels of cytokines to WT cells, with some incidences of small but significantly reduced cytokines being measured, particularly in the levels of GMCSF (Fig. 2a–c).

Interestingly, when the TRIF pathway agonist Poly(I:C) was used, there was no overall significant effect of genotype on the levels of cytokines in the tissue culture media (P = 0.066, Supplementary Fig. S2). Increased cytokine levels were also detected in the tissue culture media of LRRK2 G2019S monocytes at an earlier (6 h) timepoint following LPS stimulation (P = 0.002, Supplementary Fig. S3). Intriguingly, at this earlier timepoint there was also a significant increase in GMCSF, IL1RA, IL8, CCL3, CCL4 and TNFa in the LRRK2 KO cells (Supplementary Fig. S3). There was no difference in the baseline expression of TLR4 between the different monocyte genotypes, and LPS increased TLR4 levels similarly in all genotypes (Supplementary Fig. S4A). In contrast, LPS treatment did not affect levels of LRRK2 in the differentiated WT or G2019S monocytes (Supplementary Fig. S4B). Importantly, a significant effect of genotype (P = 0.002) could be confirmed with the second set of available subclones for the three different cell lines stimulated with LPS, and again the effect of genotype was driven by increased cytokine levels in the tissue culture media of the cells with the LRRK2 G2019S mutation (Supplementary Fig. S5). Stimulation with LPS increased the proportion of classical monocytes (Supplementary Fig. S6A), with a reduction in intermediate (Supplementary Fig. S6B) and non-classical (Supplementary Fig. S6C) monocytes and the effect was similar across the different LRRK2 genotypes. The same result of increased cytokines/chemokines in the tissue culture for the LRRK2 G2019S compared to WT cells was also observed with 50 ng/ml LPS (multivariate P = 0.006, Supplementary Fig. S7), and following additional differentiation to adherent macrophages and subsequent stimulation with 500 ng/ml LPS (multivariate P = 0.003, Fig. 2d). The levels of cytokines in the tissue culture media from the unstimulated cells were generally below the detection level of the multiplex ELISA assay, thus, whether LRRK2 G2019S potentiates cytokine release even in the absence of TLR activation could not be determined.

LRRK2 kinase inhibitors do not suppress TLR-stimulated cytokines

As the LRRK2 G2019S mutation increases the kinase activity of LRRK2, small-molecule inhibitors of LRRK2 were employed to determine their efficacy in preventing TLR-mediated cytokine release. Monocytes with the LRRK2 G2019S mutation were treated with TLR agonists in the presence or absence of MLi2 or PF06447475 for 24 h. Surprisingly, neither inhibitor had an effect on the cytokine levels in LPS-stimulated monocytes, (P = 0.402, Fig. 3a) or in G2019S monocytes treated with Pam3CSK4 (P = 0.112) (Supplementary Fig. S8A). There was also no effect of MLi2 on the tissue culture media levels of cytokines for the WT (P = 0.358, Supplementary Fig. S8B), or LRRK2 KO (P = 0.794, Supplementary Fig. S8C) cells treated with LPS. Despite a lack of effect of MLi2 on secreted cytokine levels, two-way ANOVA indicated an overall significant effect of MLi2 treatment on TLR4 expression, with an increase observed in the WT and G2019S monocytes (P = 0.004). However, differences in TLR4 levels between these groups were not significantly different following post hoc testing (Supplementary Fig. S9). Parallel immunoblotting for phosphorylation of the LRRK2 pharmacodynamic biomarker site serine 935 showed a marked reduction with LRRK2 inhibitors, confirming they were functional in the monocyte cell lines at the concentrations employed (Fig. 3b). In case the iPSC-derived monocytes may not fully capture all the features of primary human monocytes, the effect of the LRRK2 inhibitors was also tested in monocytes isolated from peripheral blood mononuclear cells obtained from six healthy blood donors. Isolated monocytes were treated for 24 h with LPS in the presence or absence of the LRRK2 inhibitors PF06447475 and MLi2. Multivariate analysis of the resulting data revealed a significant overall effect of inhibitor treatment on cytokine levels (P = 0.023), however, no significant differences
were observed with post hoc testing for any of the individual cytokines (Fig. 3c). A robust reduction in both LRRK2 S935 and Rab10 T73 phosphorylation was observed in parallel immunoblots, confirming the inhibitors were functional (Fig. 3d). The LRRK2 inhibitor experiments were then repeated following differentiation of the LRRK2 G2019S monocytes into macrophages, with cells again stimulated with LPS in the presence or absence of MLI2. Consistent with the results for monocytes, MLI2 inhibitor treatment did not affect the levels of cytokines in the tissue culture media from LRRK2 G2019S differentiated macrophages stimulated with LPS ($P = 0.350$, Supplementary Fig. S10). We also treated primary monocyte-derived macrophages with TLR
agonists LPS, Pam3CSK4 or R848 in the presence or absence of ML12, PF06447475 and GSK2578215A LRRK2 inhibitors. Again, however, no significant effect of LRRK2 inhibitors was observed for any of the treatment conditions (LPS P = 0.937, Pam3CSK4 P = 0.290, R848 P = 0.154) despite a robust reduction in LRRK2 S935 and Rab10 T73 phosphorylation with inhibitor treatment (Supplementary Fig. S11). For all the above experiments, the LRRK2 inhibitors were employed for 24 h. Thus, we also aimed to determine the effect of more chronic LRRK2 inhibition on the levels of LPS-stimulated cytokines. Primary human monocytes were again differentiated to macrophages, but this time LRRK2 kinase inhibitors were added every 48 h throughout the 7 days of differentiation and prior to stimulation with LPS. Despite prolonged inhibitor treatment, no significant effect of LRRK2 inhibition on the levels of LPS-stimulated cytokines was observed (Supplementary Fig. S12A). In parallel immunoblots, chronic LRRK2 inhibitor treatment was associated with a significant reduction in both S935 phosphorylated LRRK2 and T73 phosphorylated Rab10 (Supplementary Fig. S12B, C). Chronic LRRK2 inhibitor treatment also had no significant effect on the total levels of LRRK2 (Supplementary Fig. S12D) or Rab10 (Supplementary Fig. S12E).

IFNg increases LRRK2 and Rab10 T73 phosphorylation in macrophages

We next aimed to determine if LRRK2 inhibitors may show more effect in macrophages with elevated levels of LRRK2 following treatment with IFNy. Treatment of primary monocyte-derived macrophages with IFNy resulted in a significant approximately four times increase in the levels of LRRK2 protein (Fig. 4a), and a corresponding increase in the phosphorylation of Rab10 at T73 (Fig. 4b) compared to untreated cells. Further stimulation of IFNy treated cells with LPS resulted in a significant increase in the levels of IL1β, IL6, CCXCL10 and TNFa compared to those treated with LPS or IFNy alone (Fig. 4c). In line with the known effect of IFNy to induce a proinflammatory monocyte phenotype, the levels of IL10 were also significantly decreased in the dual treated macrophages (Fig. 4c). Levels of other cytokines remained unchanged between the LPS or the LPS plus IFNy groups. ML12 was then used to determine whether the five cytokines significantly altered with the dual-LPS plus IFNy treatment was associated with the increased LRRK2 kinase activity in these cells. A small but significant reduction in the levels of IL1β and TNFa was observed with ML12 treatment (Fig. 4d), whereas the levels of IL6, CCXCL10 and IL10 remained unchanged. Again, LRRK2 inhibitor treatment resulted in a marked reduction in LRRK2 S935 phosphorylation (Fig. 4e).

DISCUSSION

Neuroinflammation has long been associated with brain pathology in PD. However, there is increasing recognition that peripheral inflammation may also contribute to PD pathogenesis. This recognition is being driven by discoveries showing that proteins genetically associated with PD, such as alpha-synuclein and GBA are highly expressed in peripheral immune cells and contribute to the regulation of immunity. The objective of this study was to determine how levels of LRRK2, and in particular LRRK2 kinase activity, modulate the response of human monocytes and macrophages to innate immune TLR activation, the predominant pathogen response pathway in humans. Using isogenic human iPSC-derived monocytes and macrophages, higher levels of inflammatory cytokines and chemokines were measured in tissue culture media from cells harbouring the LRRK2 G2019S mutation. Increased inflammatory cytokine levels have previously been observed in transgenic mice overexpressing LRRK2 with the R1441C and R1441G mutations and treated with the TLR4 agonist LPS. With regard to the G2019S mutation, increased cytokine levels were observed in transgenic LRRK2 G2019S mouse macrophages infected with S. typhimurium, but increased inflammation was not observed in S. typhimurium infected macrophages from LRRK2 G2019S knock-in mice. Potentiated peripheral cytokine levels were also not observed in mice overexpressing the G2019S mutation and treated with LPS. Thus, the model and pathogenic context employed likely contribute to divergent immune response outcomes. Importantly, however, clinical studies have provided evidence for increased inflammation in asymptomatic carriers of the LRRK2 G2019S mutation, and regular use of non-steroidal anti-inflammatory medication may reduce the penetrance of LRRK2-associated PD.

Mechanistically, our hypothesis was that potentiated inflammation associated with the G2019S mutation would be due to the two- to threefold increase in the kinase activity of LRRK2 that the G2019S mutation imparts. However, under the experimental conditions employed, we did not observe a robust anti-inflammatory effect of LRRK2 kinase inhibitors clearly suggesting that potentiated cytokine levels with the G2019S mutation occurred independently of LRRK2 kinase activity. These results differ from studies focused on neuroinflammation that have used microglia to demonstrate an anti-inflammatory effect of LRRK2 kinase inhibitors. Interestingly, the expression of LRRK2 appears substantially lower in microglia compared to monocytes/macrophages and it will be of interest to determine the extent that any LRRK2 inflammatory regulating pathway may be conserved in these related but different cell types. This may be important in regard to the treatment of PD and/or understanding the mechanism of action of LRRK2 kinase inhibitors, particularly as recent rodent and clinical studies support an important role for peripheral myeloid cells in PD pathogenesis. In contrast, the ability to attenuate neuroinflammation without an effect on peripheral TLR-mediated immunity may even be of benefit for the...
**Fig. 2 Potentiated cytokines in G2019S monocytes and macrophages.** Multiplex ELISA assay was used to measure levels of the indicated inflammatory cytokines in tissue culture media from LRRK2 wild type (WT, green bars), G2019S (blue bars) and knockout (KO, orange bars) monocytes following 24 h stimulation with 500 ng/ml LPS (a), 1 μg/ml pam3CSK4 (b) and 1 μg/ml CLO97 (c). d LRRK2 wild-type and G2019S monocytes were further differentiated to macrophages and cytokines in the tissue culture media were measured following 24 h stimulation with 500 ng/ml LPS. For all graphs, the data are expressed as the percent change for a particular cytokine relative to LRRK2 wild type, which was set at 100%. Graphs show mean ± SEM and are based on n = 3 technical replicates and representative of at least two biological replicates.

*Indicates P < 0.05 for G2019S compared to wild type. #Indicates P < 0.05 for LRRK2 knockout compared to wild type.
clinical translation of LRRK2 inhibitors by reducing the potential for unwanted side effects.

In addition to the lack of effect of LRRK2 inhibitors, we also found no effect of LRRK2 KO on TLR-stimulated cytokines. This result is consistent with early work showing no effect on TLR-stimulated cytokine production in bone marrow-derived macrophages from LRRK2 knockout mice. We did however observe an impairment in the phagocytosis of latex beads in the LRRK2 knockout macrophages at a longer 16 h timepoint. A recent study using a similar isogenic human iPSC-derived macrophage...
Fig. 3 LRRK2 kinase inhibitors do not affect TLR-mediated inflammation. a Multiplex ELISA assay was used to measure levels of the indicated inflammatory cytokines in tissue culture media from LRRK2 G20195 cells that were treated with DMSO (green bars), or the LRRK2 kinase inhibitors PF64447475 (0.5 μM, blue bars) or ML12 (0.1 μM, orange bars) for 24 h following stimulation with 500 ng/ml LPS. b Immunoblotting of the LRRK2 pharmacodynamic biomarker site, serine 935 was performed in parallel sets of differentiated monocytes. c Multiplex ELISA assay was used to measure levels of the indicated inflammatory cytokines in tissue culture media from primary monocytes isolated from healthy donor peripheral blood mononuclear cells that were cells that were treated with DMSO (green bars), or the LRRK2 kinase inhibitors PF64447475 (0.5 μM, blue bars) or ML12 (0.1 μM, orange bars) for 24 h following stimulation with 500 ng/ml LPS. Immunoblotting was used to measure LRRK2 serine 935 (d) and Rab10 threonine 73 (e) phosphorylation in primary monocytes isolated from healthy blood donors and treated as above (n = 6). Representative immunoblots are shown. Graphs show mean ± SEM and data is expressed as the percent change relative to DMSO treated cells which are set at 100%. Cytokine graphs are based on n = 3 technical replicates and representative of at least two biological replicates. *P < 0.05 compared to DMSO.

approach, that more comprehensively evaluated phagocytosis in response to different pathogenic stimuli did not find impaired phagocytosis with LRRK2 KO at more acute 2-h timepoints55. However, LRRK2 was localised to phagosomes at later stages of maturation following the induction of phagocytosis. In contrast, microglia from LRRK2 KO mice did show impaired phagocytosis via dysregulation of WAVE2 at acute timepoints56. Murine studies have also demonstrated that a loss of LRRK2 results in impaired maturation following the induction of phagocytosis. In contrast, have also demonstrated that a loss of LRRK2 results in impaired

METHODS

Induced pluripotent stem cells (iPSCs)

iPSCs were derived with informed written consent from a PD patient with the G20195 mutation. Characterisation of these cells, along with the corresponding Zinc-finger gene-corrected isogenic control cell line, and LRRK2 knockout cell line on the same isogenic background have been described previously56,58. Two subclones of each cell line were available. Ethics approval for use of the iPSCs was provided by the University of Sydney Human Research Ethics Committee (#2017/094). iPSCs were maintained on Geltrans and cultured using Essential 8 media (both Thermofisher) with manual passaging under a stereomicroscope (Nikon SMZ1270).

Differentialiation of iPSCs to monocytes

iPSCs were differentiated into monocytes following the protocol of Yanagimachi et al.64, following the schematic outlined in Supplementary Fig. S13. All growth factor and cytokine supplements were purchased from Miltenyi Biotech. Cell culture supernatant containing CD14 expressing cells was collected on days 18, 22, 26 and 30 and either used immediately for experiments or cryopreserved (using RPMI supplemented with 20% FBS and 10% DMSO) for experiments later. Cryopreserved cells were allowed to recover for 2 h prior to isolation for experiments.

Isolation of primary peripheral blood mononuclear cells (PBMCs)

For the isolation of primary PBMCs, residual buffy coat samples were obtained from healthy donors to the Australian Red Cross Blood Service. Ethics approval for studies using human blood samples was provided by the University of Sydney Human Research Ethics Committee (#2017/857). PBMCs were isolated using Ficoll-Paque (GE Healthcare) and centrifugation (400 × g for 30 min with acceleration 4 and brake 0) in a swing bucket rotor. Isolated PBMCs were resuspended in media and used for the immunomagnetic isolation of monocytes.

Immunomagnetic isolation of monocytes

Monocytes were positively selected from differentiated iPSC tissue culture media or primary PBMCs using CD14 microbeads in conjunction with magnetic-activated cell sorting (MACS) as per the manufacturer instructions (Miltenyi Biotech). Monocytes were used for experiments or differentiated to macrophages over a further 7 days using RPMI-1640 (Thermofisher) supplemented with 10% FBS (Thermofisher) and 100 ng/ml M-CSF.

Cell treatments

Depending on the application, from 2.5 × 104 to 1 × 106 CD14+ cells were used for experiments. TLR agonists (Invivogen) were used at the following concentrations; lipopolysaccharide (LPS) (TLR4 agonist, 0.5 μg/ml), Pam3CSK4 (TLR1/2 agonist, 1 mg/ml), CL097 (TLR7/8 agonist, 1 mg/ml), R848 (TLR7/8 agonist, 1 mg/ml) and Poly(I:C) (TLR3 agonist, 10 mg/ml). LRRK2 kinase inhibitors (Tocris) were used at the following concentrations; lipopolysaccharide (LPS) (TLR4 agonist, 0.5 μg/ml), Pam3CSK4 (TLR1/2 agonist, 1 mg/ml), CL097 (TLR7/8 agonist, 1 mg/ml), R848 (TLR7/8 agonist, 1 mg/ml) and Poly(I:C) (TLR3 agonist, 10 mg/ml). LRRK2 kinase inhibitors (Tocris) were used at the following concentrations; lipopolysaccharide (LPS) (TLR4 agonist, 0.5 μg/ml), Pam3CSK4 (TLR1/2 agonist, 1 mg/ml), CL097 (TLR7/8 agonist, 1 mg/ml), R848 (TLR7/8 agonist, 1 mg/ml) and Poly(I:C) (TLR3 agonist, 10 mg/ml). LRRK2 kinase inhibitors (Tocris) were used at the following concentrations; lipopolysaccharide (LPS) (TLR4 agonist, 0.5 μg/ml), Pam3CSK4 (TLR1/2 agonist, 1 mg/ml), CL097 (TLR7/8 agonist, 1 mg/ml), R848 (TLR7/8 agonist, 1 mg/ml) and Poly(I:C) (TLR3 agonist, 10 mg/ml).

Multiplex cytokine ELISA assays

Cytokines were assayed using magnetic Bio-Plex Pro Human Cytokine 27-plex kits (Bio-Rad) as per the manufacturers’ instructions. ELISA assays were performed at least in triplicate and data presented as either the cytokine

Published in partnership with the Parkinson’s Foundation
Fig. 4  Interferon gamma increases LRRK2 levels and Rab10 phosphorylation. Primary monocytes from healthy donors were differentiated to macrophages and then treated with 100 U/ml interferon gamma for 48 h. Immunoblot analysis was then performed for LRRK2 (a) and total and T73 phosphorylated Rab10 (b). Representative immunoblots are shown. Graphs show mean ± SEM (N = 6) and data is expressed as the percent change relative to untreated cells, which are set at 100%. **P < 0.01, ***P < 0.001 compared to untreated cells.

c Primary monocytes were differentiated to macrophages and then treated with or without 100 U/ml interferon gamma for 24 h followed by treatment with or without 500 ng/ml LPS for a further 24 h. Multiplex ELISA assays were used to measure levels of the indicated inflammatory cytokines in tissue culture media. Graphs show mean ± SEM (n = 6). *P < 0.05, **P < 0.001, compared to cells treated only with LPS.

d Primary monocytes were differentiated to macrophages and then treated with 100 U/ml interferon gamma for 24 h followed by 500 ng/ml LPS for a further 24 h in the presence or absence of 0.1 μM MLi2. Multiplex ELISA assays were used to measure levels of the indicated inflammatory cytokines in tissue culture media. Graphs show data from the different individuals (n = 6). *P < 0.05 compared to DMSO.

e Representative immunoblot of total and S935 phosphorylated LRRK2 following treatment with or without 0.1 μM MLi2.
levels in pmol, or the percent change in cytokine levels compared to wild-type cells. Samples from different groups were distributed equally across ELISA plates. Cytokines outside the limit of detection were not included in analyses, consequently not all graphs show the complete set of 27 cytokines.

**Cell lysis and immunoblotting**
Cells were lysed by buffer containing 50 mM Tris-HCL pH 7.5, 1 mM EGTA, 1 mM EDTA, 1 mM sodium orthovanadate, 50 mM sodium fluoride, 5 mM sodium pyrophosphate, 0.27 M sucrose, 1 mM benzamidine, 1 mM phenylmethylsulfonyl fluoride (PMSF) and 1% (v/v) Triton X-100 and clarified by centrifuging at 12,000 × g for 20 min at 4 °C. Protein concentration was determined using a bicinchoninic assay ( Pierce) and samples were made up in 1× NuPAGE LDS buffer (Thermofisher). Samples were then separated using 4–12% Novex Tris-glycine gels (Thermofisher) and transferred onto nitrocellulose membrane (Biorad). Membranes were blocked with 5% skim milk powder in Tris-buffered saline with 0.1% (v/v) Tween 20 (TBST). Where indicated, membranes were probed for total LRRK2 (N241A/34, Neumonab), phosphorylated LRRK2 pSer935 (UDD2, Abcam), total Rab10 (D36C4, Cell Signaling Technology), phosphorylated Rab10 pThr73 (M2R-F21, Abcam), and β-actin as a loading control (AC-15, Abcam). Primary antibodies were used at 1:1000 dilution in 5% skim milk in TBST. Anti-mouse and anti-rabbit horseradish peroxidase secondary antibodies (Biorad) were used at 1:5000 dilution. Protein levels in pmol, or the percent change in cytokine levels compared to wild-type cells. Samples from different groups were distributed equally across ELISA plates. Cytokines outside the limit of detection were not included in analyses, consequently not all graphs show the complete set of 27 cytokines.

**Flow cytometry**
Cells were pelleted by centrifugation (300 × g for 4 min at 4 °C), washed with fluorescence-activated cell sorting (FACS) buffer (1× PBS,1 mM EDTA, 25 mM HEPES, and 1% heat-inactivated FBS; pH 7.4) and then incubated with Fc-Blocking Reagent (Miltenyi Biotech) for 10 min at 4 °C. Cells were washed as above and then resuspended in FACS buffer with fluorochrome-conjugated monoclonal antibodies for 20 min at 4 °C. The antibodies used were PE-Cy7-conjugated anti-CD14, BV421-conjugated anti-CD16, BV510-conjugated anti-CCR2, BV711-conjugated anti-CD68, PE- CF594-conjugated anti-CD163 (all from Becton Dickinson), and PE-conjugated anti-TRIM4 and Alexa Fluor 488-conjugated anti-HLA-DR (both from BioLegend). Following antibody incubation, cells were fixed with 2% PFA for 10 min, washed again with FACS buffer and finally resuspended in 350 ml FACS buffer for acquisition. Data were acquired using an LSR Fortessa flow cytometer (Becton Dickinson) and analysed using FlowJo software (TreeStar). At least 10,000 events were captured per condition.

**Phagocytosis assay**
A 4% solution of GFP-labelled latex beads with a mean particle size of 0.5 μm (HL5530) was used to assess phagocytosis. Macrophages were incubated for 3 h and 16 h, washed with live-cell imaging solution (Thermofisher) and stained with CellMask Deep Red (Thermofisher) as per manufacturer instructions. After 15 min, cells were fixed with 4% paraformaldehyde and DAPI was used to stain the nucleus. Fluorescence intensity was measured using a C2 confocal microscope at ×40 magnification (Nikon). Fiji ImageJ particle analysis tool was then used to determine the average intensity, average number and average area of fluorescent puncta formed by the accumulation of latex beads per CellMask positive cell. CellMask was also used to exclude extracellular signals. At least five images were measured per cell line with at least ~20–50 cells analysed per image.

**Statistical analysis**
Statistical analysis was performed using SPSS (IBM) or Prism (GraphPad). As different cytokines were expressed at markedly different levels, ELISA data were standardised by expressing cytokine levels as a percentage compared to WT or DMSO treated cells as appropriate. Multivariate analysis was then used to determine the effect of treatment on cytokine levels. A significant overall effect was accepted at P < 0.05 using Wilks’ Lambda. Post hoc pairwise comparisons of the estimated marginal means were performed to determine significant differences compared to the wild type or DMSO treated cells. For some comparisons, where indicated, one-way ANOVA with Dunnett’s post hoc test, two-way ANOVA with the Tukey post hoc test, or t tests were used. For all analyses, significance was accepted at P < 0.05. Graphs show mean ± SEM.

**Reporting summary**
Further information on research design is available in the Nature Research Reporting Summary linked to this article.

**DATA AVAILABILITY**
The datasets generated during and/or analysed during this study are available from the corresponding author on reasonable request.

Received: 12 October 2020; Accepted: 17 February 2022;
Published online: 28 March 2022

**REFERENCES**
1. Gasser, T. Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert Rev. Mol. Med. 11, e22 (2009).
2. Sheng, Z. et al. Ser1292 autoprophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Sci. Transl. Med. 4, 151ra161 (2012).
3. Steger, M. et al. Phosphoproteomics reveals that Parkinson’s disease kinase LRRK2 regulates a subset of Rab GTPases. eLife 5, https://doi.org/10.7554/eLife.12813 (2016).
4. Healy, D. G. et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study. Lancet Neurol. 7, 583–590 (2008).
5. Nalls, M. A. et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Nat. Genet. 46, 989–993 (2014).
6. Simon-Sanchez, J. et al. Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nat. Genet. 41, 1308–1312 (2009).
7. Kluss, J. H., Mamas, A. & Cookson, M. R. LRRK2 links genetic and sporadic Parkinson’s disease. Biochemical J. 47, 651–661 (2019).
8. Sharma, M. et al. Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology 79, 659–667 (2012).
9. Di Maio, R. et al. LRRK2 activation in idiopathic Parkinson’s disease. Sci. Transl. Med. 10, https://doi.org/10.1126/scitranslmed.aar5429 (2018).
10. Atashrazm, F. & Dzamko, N. LRRK2 inhibitors and their potential in the treatment of Parkinson’s disease: current perspectives. Clin. Pharm. 8, 177–189 (2016).
11. West, A. B. Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic. Mov. Disord. 30, 180–189 (2015).
12. Zhao, Y. & Dzamko, N. Recent developments in LRRK2-targeted therapy for Parkinson’s disease. Drugs 79, 1037–1051 (2019).
13. Tolosa, E., Villa, M., Klein, C. & Rascol, O. LRRK2 in Parkinson disease: challenges of clinical trials. Nat. Rev. Neurol. 16, 97–107 (2020).
14. Alessi, D. R. & Sammler, E. LRRK2 kinase in Parkinson’s disease. Science 360, 36–37 (2018).
15. Wallings, R. L., Herrick, M. K. & Tansey, M. G. LRRK2 at the Interface between peripheral and central immune function in Parkinson’s. Front. Neurosci. 14, 443 (2020).
16. Dzamko, N. & Halliday, G. M. An emerging role for LRRK2 in the immune system. Biochemical Soc. Trans. 40, 1134–1139 (2012).
17. Gardet, A. et al. LRRK2 is involved in the IFN-gamma response and host response to pathogens. J. Immunol. 185, 5577–5585 (2010).
18. Hakimi, M. et al. Parkinson’s disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. J. Neuroimmune Pharmacol. 118, 795–808 (2021).
19. Fan, Y. et al. Interrogating Parkinson’s disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neurophils. Biochemical J. 475, 23–44 (2018).
20. Atashrazm, F. et al. LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson’s disease patients. Mov. Disord. 34, 406–415 (2019).
21. Thevenet, J., Pescini Gobert, R., Houft van Huijsduijnen, R., Wiessner, C. & Sagot, Y. J. Regulation of LRRK2 expression points to a functional role in human monocyte maturation. PLoS ONE 6, e21519 (2011).
22. Dzamko, N. et al. The IkapapB kinase family phosphorylates the Parkinson’s disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling. PLoS ONE 7, e39132 (2012).
Litteljohn, D. et al. The impact of murine LRRK2 transgene overexpression in the brain. *Neuroscience* **12**, 1063–1070 (2011).

Fava, V. M. et al. A missense LRRK2 variant is a risk factor for excessive inflammatory responses in leprosy. *PloS Neglected Tropical Dis*. **10**, e004412 (2016).

Hartlvo, A. et al. LRRK2 is a negative regulator of Mycobacterium tuberculosis phagosome maturation in macrophages. *EMBO J*. **37**,https://doi.org/10.10252/emby.201709894 (2018).

Weindel, C. G. et al. LRRK2 maintains mitochondrial homeostasis and regulates innate immune responses to Mycobacterium tuberculosis. *elife* **9**,https://doi.org/10.7554/elife.51071 (2020).

Shutinoski, B. et al. Lrrk2 alleles modulate inflammatory responses in mice in a sex-dependent manner. *Sci. Transl. Med.* **11**,https://doi.org/10.1126/scitransmed.aaoz929 (2019).

Hui, K. Y. et al. Functional variants in the LRRK2 gene confer shared effects on risk for Crohn’s disease and Parkinson’s disease. *Sci. Transl. Med.* **10**,https://doi.org/10.1126/scitransmed.aatz7955 (2018).

Ahmadi Rastegar, D. & Dzamko, N. Leucine rich repeat kinase 2 and innate immunity. *Front. Neurosci*. **14**, 193 (2020).

Dzamko, N., Gezy, C. L. & Halliday, G. M. Inflammation is genetically implicated in Parkinson’s disease. *Neuroscience* https://doi.org/10.1016/j.neuroscience.2014.10.028 (2014).

Cabezudo, D., Baeckelandt, V. & Lobbestael, E. Multiple-hit hypothesis in Parkinson’s disease: LRRK2 and inflammation. *Front. Neurosci*. **14**, 376 (2020).

Patrick, K. L., Bell, S. L., Weindel, C. G. & Watson, R. O. Exploring the “Multiple Hit Hypothesis” of neurodegenerative disease: bacterial infection comes up to bat. *Front. Cell Infect. Microbiol*. **9**, 138 (2019).

Rolli-Derkinderen, M. et al. Is Parkinson’s disease a chronic low-grade inflammatory bowel disease? *J. Neurol.* **267**, 2207–2213 (2020).

Hallett, P. J., Engeland, S. & Isacson, O. Lipid and immune abnormalities causing age-dependent neurodegeneration and Parkinson’s disease. *J. Neuroinflammation* **16**, 153 (2019).

Brockmann, K. et al. Infectious profile in LRRK2-associated prodromal and clinical PD. *J. Neuroinflammation* **13**, 122 (2016).

Dzamko, N., Rowe, D. B. & Halliday, G. M. Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers. *Mov. Disord.* **31**, 889–897 (2016).

Brockmann, K. et al. Infectious profile discriminates clinical subtypes in LRRK2-associated Parkinson’s disease. *Eur. J. Neurol*. **24**, 427–4462 (2017).

San Luciano, M. et al. Nonsteroidal anti-inflammatory use and LRRK2 Parkinson’s disease penetrance. *Mov. Disord.* **35**, 1755–1764 (2020).

McGeer, P. L., Itagaki, S., Boyes, B. E. & McGeer, E. G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson disease. *J. Neurosci.* **33**, 122 (2013).

Zhang, Q. et al. Commensal bacteria direct selective cargo sorting to promote symbiosis. *Nat. Immunol.* **16**, 918–926 (2015).

Puccini, J. M. et al. Leucine-rich repeat kinase 2 modulates neuroinflammation and neurotoxicity in models of human immunodeficiency virus 1-associated neurocognitive disorders. *J. Neurosci.* **35**, 5271–5283 (2015).

Schapansky, J., Nardozzi, J. D., Felizia, F. & LaVoie, M. J. Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy. *Hum. Mol. Genet.* **23**, 4201–4214 (2014).

Nichols, R. J. et al. 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson’s disease-associated mutations and regulates cytoplasmic localization. *Biochemical J.* **425**, 393–404 (2010).

Madureira, M., Connor-Robson, N. & Wade-Martins, R. “LRRK2: autophagy and lysosomal activity”. *Front. Neurosci.* **14**, 498 (2020).

Singh, A., Zhi, L. & Zhang, H. LRRK2 and mitochondria: recent advances and current views. *Brain Res.* **1702**, 96–104 (2019).

Rivero-Rios, P. et al. Alterations in late endocytic trafficking related to the pathobiology of LRRK2-linked Parkinson’s disease. *Biochemical Soc. Trans.* **43**, 390–395 (2015).

Sanders, L. H. et al. LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson’s disease patients: reversal by gene correction. *Neurobiol. Dis.* **62**, 381–386 (2014).

Bieri, G. et al. LRRK2 modifies alpha-syn pathology and spread in mouse models and human neurons. *Acta Neuropathologica* **137**, 961–980 (2019).

Yangamachi, M. D. et al. Robust and highly-efficient differentiation of functional monocyte cells from human pluripotent stem cells under serum- and feeder-free conditions. *PloS ONE* **8**, e59243 (2013).

**ACKNOWLEDGEMENTS**

This work was jointly funded by the Michael J Fox Foundation for Parkinson’s disease research and the Shake It Up Australia Foundation (#14243 awarded to N.D. and B.S.). The isogenic iPSC lines were derived under a grant from the California Institute for Regenerative Medicine (RT2-1965 to B.S.). D.A.R. was funded by a PhD scholarship from the University of Sydney. G.M.H. holds a NHMRC senior leadership fellowship (#176607) The Dementia and Movement Disorders Laboratory is supported by ForeFront, a collaborative research group dedicated to the study of non-Alzheimer disease degenerative disorders, funded by NHMRC grants (#1037746, #1095127 and #1132524). We acknowledge Sydney Cytometry for access to technical assistance. We acknowledge the use of instruments and the scientific and technical assistance of Microscopy Australia at the University of Sydney Microscopy and Microanalysis research facility, a facility that is funded by the University and state and federal governments.

**AUTHOR CONTRIBUTIONS**

Study concept and design: N.D., B.S. and G.M.H. Experimental work: D.A.R., G.P., L.P.H., J.G., S.K., S.Z., N.D. Statistical analysis of data: N.D., D.A.R. and L.P.H. Initial drafting of manuscript: N.D., D.A.R., L.P.H., B.S. and G.M.H. Editing and approval of submitted manuscript: all authors.

**COMPETING INTERESTS**

The authors declare no competing interests.
